Trigonelline (TRG), a niacin related compound, is a natural constituent of coffee accounting for approximately 1% dry matter in roasted beans. Studies exploring the effects of this bioactive compound on mammalian cells are limited. However, treatment of neuroblastoma cells with TRG resulted in increased formation of neurites and TRG inhibits invasion of hepatoma cells. The purpose of these studies was to determine if TRG also has endocrine actions in mammalian cells. Specifically, we sought to determine if TRG exhibits estrogenic properties by activating the estrogen receptor (ER). Proliferation of ER‐dependent breast cancer (MCF‐7) cells was used to screen for potential estrogenic actions of the compound. TRG stimulated MCF‐7 cell proliferation in a dose responsive manner and significantly enhanced cell growth at concentrations as low as 100pM. Co‐treatment of MCF‐7 cells with TRG and ICI, an ER antagonist, inhibited TRG induced cell proliferation. In addition, when cells were co‐treated with suboptimal doses of estradiol and TRG, an additive enhancement of MCF‐7 growth was observed. Estrogen response element (ERE)‐reporter assays and modulation of ER target genes (pS2, progesterone receptor, and cyclin D1) were also analyzed. These data demonstrate that TRG at low concentrations stimulates MCF‐7 cell growth and that this effect is mediated through ER. Thus, we have identified TRG as a novel phytoestrogen.
Read full abstract